Skip to main content
. 2017 Jun 21;23(23):4200–4210. doi: 10.3748/wjg.v23.i23.4200

Figure 4.

Figure 4

In vivo effect of dexamethasone, cholesteryl butyrate and dexamethasone cholesteryl butyrate-solid lipid nanoparticles on bodyweight and disease activity index. Animals received no treatment (control), DSS alone (DSS), or a combination of DSS and Dx (Dx, 0.0001 mg/g bw for 3 d), DSS and Cb (Cb, 0.004 mg/g bw for 3 d) and DSS and DxCb-SLN (DxCb-SLN, 0.0001 mg/g bw:0.004 mg/g bw for 3 d). After 7 d, DSS was replaced with a water cycle (ad libitum) for another 7 d. Body weight of the mice was recorded daily (A) and the disease activity rate at day 9 (B). bP < 0.01, vs control; cP < 0.05; dP < 0.01, vs DSS. Dx: Dexamethasone; Cb: Cholesteryl butyrate; DxCb-SLN: Dexamethasone cholesteryl butyrate-solid lipid nanoparticles; DSS: Dextran sulfate sodium.